Adocia (LTS:0QAI) FFO


LTS:0QAI Adocia LTS:0QAI
33 GF Score
Price €4.19
GF Value €0.90
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0QAI
33GF Score
Adocia LTS:0QAI
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adocia (LTS:0QAI) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €4.19 is trading 365.8% above its estimated GF Value™ of €0.90. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for LTS:0QAI:

  • FFO:
  • GF Value™: €0.90 vs. price of €4.19 (365.8% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Other Exchanges ADOC:FranceA89:Germany
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
33GF Score

Get the complete analysis for LTS:0QAI

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.19
Price
€0.90
GF Value